Keep an eye on the price momentum at Adaptimmune Therapeutics

Keep an eye on the price momentum at Adaptimmune Therapeutics

Article image

Anyone familiar with stock market screeners will know that shares in Adaptimmune Therapeutics (NSQ:ADAP) have been in an uptrend in recent months, with strong relative price strength on a 1-month, 6-month and 12-month basis.

Knowing exactly what drives relative strength in share prices (as well as how to find shares with good strength) can help you find profitable trading ideas. 

Adaptimmune Therapeutics operates in the Biotechnology & Medical Research industry and in terms of relative price strength the stock has performed well against the market over the past year:

  • 1 Month: 229.5%
  • 6 Months: 980.6%
  • 12 Months: 199.6%

Why does that matter? Relative strength is a useful tool for technical traders and investors, providing an instant measure of how a stock has performed in comparison with a benchmark.

Studies by leading experts on momentum show that stocks with the strongest price strength tend to keep up the pace for anywhere up to one year as investors increasingly buy in to them.

Finding shares with a given relative price against your local share index is best done with a screening tool, which help you discover shares you may have never heard of.


What does this mean for potential investors?

Adaptimmune Therapeutics is currently among the stocks with the strongest six-month and one-year relative price strength in the market. But momentum on its own is no guarantee of future returns. 

To get a better idea about whether this momentum will continue, it's worth doing some investigation yourself. Indeed, we've identified some areas of concern with Adaptimmune Therapeutics that you can find out about here.


About us

Stockopedia helps individual investors make confident, profitable choices in the stock market. Our StockRank and factor investing toolbox unlocks institutional-quality insights into thousands of global stocks. Voted “Best Investment Research Tools” and “Best Research Service” at the 2021 UK Investor Magazine awards.

Adaptimmune Therapeutics's StockRank™

Momentum TrapSpeculative

Adaptimmune Therapeutics's StockRank™

With a StockRank of 34, Adaptimmune Therapeutics is in the bottom 34% of the 9,664 stocks we cover in North America, according to our proprietary ranking system.

See the full StockReport

Absolutely Perfect

"Trialed multiple other platforms - this is by far my favourite. Other platforms do not even have half the stuff that you can find on Stockopedia. Love it!"

As per our Terms of Use, Stockopedia is a financial news & data site, discussion forum and content aggregator. Our site should be used for educational & informational purposes only. We do not provide investment advice, recommendations or views as to whether an investment or strategy is suited to the investment needs of a specific individual. You should make your own decisions and seek independent professional advice before doing so. Remember: Shares can go down as well as up. Past performance is not a guide to future performance & investors may not get back the amount invested.